name: Respiratory Allergy Profile with Total IgE in Serum, Area 16


name: Respiratory Allergy Profile with Total IgE in Serum, Area 17


name: Respiratory Allergy Profile with Total IgE in Serum, Area 18


name: Respiratory Allergy Profile with Total IgE in Serum, Area 19


name: Respiratory Allergy Profile with Total IgE in Serum, Area 20


name: Hepatitis A panel (Profile V) in Serum or Plasma


name: Hepatitis B Virus Panel (Profile VI) in Serum or Plasma


name: Hepatitis Panel in Serum or Plasma by Immunoassay


name: Diagnostic Hepatitis Panel (Profile I) in Serum or Plasma


name: Diagnostic Hepatitis Follow-up Panel (Profile II) in Serum or Plasma


name: Hepatitis Patient Management (Profile III) in Serum or Plasma


name: HAV/HBV Immune Status Panel (Profile IV) in Serum or Plasma


name: HAV/HBV Panel (Profile VII) in Serum or Plasma


name: HBV/HCV Panel (Profile VIII) in Serum or Plasma


name: HBV Prevaccination Panel (Profile X) in Serum or Plasma


name: HBV Vaccine Follow-up Panel (Profile XI) in Serum or Plasma


name: HBV Follow-up Panel (Profile XII) in Serum or Plasma


name: Hepatitis B Prenatal Panel (Profile XIII) in Serum or Plasma


name: Hepatitis C virus RNA panel in Serum or Plasma by NAA with probe detection


name: Hepatitis E virus IgG and IgM panel in serum


name: Anaplasma phagocytophilum and Ehrlichia chaffeensis IgG panel titer in serum


name: anticardiolipin IgA, IgG, and IgM antibodies panel


name: Antinuclear Antibodies (ANA) with Reflex in Serum


name: Antinuclear Antibodies (ANA) with Reflex to Multiple Confirmatory Tests in Serum


name: Antineutrophil Cytoplasmic Antibody (ANCA) Profile in Serum


name: Coxsackievirus virus group B antibody panel


name: Cortisol-Cortisone Ratio Profile in Serum or Plasma


name: Gliadin peptide IgA and IgG panel in serum


name: Herpes simplex virus antibody panel in serum


name: Inflammatory Bowel Disease - IBD Expanded Panel


name: Varicella zoster virus IgG and IgM panel in serum


name: immunoglobulin free kappa light chain in serum or plasma


name: immunoglobulin free lambda light chain in serum or plasma


name: Streptococcus pneumoniae Danish serotype antibody in serum


name: Streptococcus pneumoniae Danish serotype 1 antibody in serum


name: Streptococcus pneumoniae Danish serotype 1 IgG antibody in serum


name: Streptococcus pneumoniae Danish serotype 15B antibody in serum


name: Streptococcus pneumoniae Danish serotype 15B IgG antibody in serum


name: Streptococcus pneumoniae Danish serotype 33F antibody in serum


name: Streptococcus pneumoniae Danish serotype 33F IgG antibody in serum


name: SCL-70 extractable nuclear IgG antibody in serum


name: liver-kidney microsomal (LKM) 1 antibody in serum


name: allergy testing candida albicans igg4 antibody in serum


name: Stachybotrys chartarum IgA antibody in serum


name: Stachybotrys chartarum IgG antibody in serum


name: Treatment Center urine drug screen panel


name: Yersinia enterocolitica antibody in serum


name: Yersinia enterocolitica IgA antibody in serum


name: Yersinia enterocolitica IgG antibody in serum


name: Yersinia enterocolitica IgM antibody in serum


name: Yersinia enterocolitica O:3 antibody in serum


name: Yersinia enterocolitica O:3 IgG antibody in serum


name: Yersinia enterocolitica O:5 antibody in serum


name: Yersinia enterocolitica O:8 antibody in serum


name: Yersinia enterocolitica O:9 antibody in serum


name: Yersinia enterocolitica O:9 IgG antibody in serum


name: Tetanus/diphtheria Antibody Panel in serum


name: Epstein-Barr Acute Infection Antibodies Panel


name: Echinococcus granulosus antibody in serum


name: Echinococcus granulosus IgG antibody in serum


name: Taenia solium larva IgA antibody in serum


name: Taenia solium larva IgG antibody in serum


name: Taenia solium larva IgM antibody in serum


name: Hepatitis B virus surface antibody in serum


name: ganglioside GM1 IgA antibody titer in serum


name: ganglioside GM1 IgG antibody titer in serum


name: ganglioside GM1 IgM antibody titer in serum


name: Jo-1 extractable nuclear antibody titer in serum


name: liver kidney microsomal antibody titer in serum


name: liver kidney microsomal IgG antibody titer in serum


name: Glial nuclear type 1 antibody titer in serum


name: Scl-70 extractable nuclear antibody titer in serum


name: Sjogrens syndrome-A extractable nuclear antibody titer in serum


name: Sjogrens syndrome-B extractable nuclear antibody titer in serum


name: Celiac Disease Comprehensive Antibody Panel in Serum


name: etiocholanolone/creatinine ratio in 24 hour urine


name: androsterone/creatinine ratio in 24 hour urine


name: 11-hydroxyandrosterone/creatinine ratio in 24 hour urine


name: normetanephrine/creatinine ratio in 24 hour urine


name: magnesium/creatinine ratio in 24 hour urine


name: 11-oxo-etiocholanolone/creatinine ratio in 24 hour urine


name: phosphate to creatinine clearance ratio in 24 hour urine


name: albumin/total protein in urine by electrophoresis


name: alpha 1 globulin/total protein in urine by electrophoresis


name: alpha 2 globulin/total protein in urine by electrophoresis


name: beta globulin/total protein in urine by electrophoresis


name: gamma globulin/total protein in urine by electrophoresis


name: progressive sperm grade 1 + 2/100 sperm in semen


name: Abnormal radiologic findings on diagnostic imaging of testis


name: Borrelia burgdorferi C6 antibody in serum


name: Francisella tularensis antibody in serum


name: Francisella tularensis IgA antibody in serum


name: Francisella tularensis IgG antibody in serum


name: Francisella tularensis IgM antibody in serum


name: Francisella tularensis antibody titer in serum


name: Francisella tularensis IgA antibody titer in serum


name: Francisella tularensis IgG antibody titer in serum


name: Francisella tularensis IgM antibody titer in serum


name: yellow fever virus antibody titer in serum


name: liver kidney microsomal 1 antibody titer in serum by immunofluorescence


name: liver kidney microsomal 2 antibody titer in serum by immunofluorescence


name: neutrophil cytoplasmic atypical perinuclear antibody titer in serum


name: purkinje cells cytoplasmic antibody type 1 titer in serum


name: purkinje cells cytoplasmic antibody type 2 titer in serum


name: purkinje cells cytoplasmic antibody-Tr titer in serum


name: neuronal nuclear type 1 antibody in serum


name: neuronal nuclear type 2 antibody in serum


name: neuronal nuclear type 2 IgG antibody in serum


name: neuronal nuclear type 3 antibody in serum


name: Hepatitis C virus antibody band pattern interpretation in serum by immunoblot


name: urine acylcarnitine/free carnitine(C0) ratio


name: multiple gestation, number of chorions and amnions are both equal to number of fetuses


name: Newborn affected by fetal inflammatory response syndrome


name: Disturbances of chlorine balance of newborn


name: milestone: points to object to draw attention to it


name: milestone: turns and looks at adult if something new happens


name: milestone: climbs up a playground ladder


name: milestone: elicits attention with 'look at me'


name: milestone: grasps crayon with thumb and fingers instead of fist


name: low-moderate internal carotid artery stenosis (16-49%) calculated by NASCET criteria


name: basophils per 100 leukocytes in body fluid


name: Hepatitis B virus core antibody in serum from donor


name: blood group antibody detection in serum or plasma


name: Less than 10 fetal movements in 12 hours


name: Low number of red blood cells or hemoglobin


name: Increased proportion of HLA DR+ CD4+ T cells


name: Anti-granulocyte-macrophage colony stimulating factor antibody positivity


name: Weakness of superior oblique muscle of eye


name: Increased stool alpha1-antitrypsin concentration


name: Abnormally loud pulmonic component of the second heart sound


name: Compensatory head tilt to the right shoulder


name: Compensatory head tilt to the left shoulder


name: Weakness of superior rectus muscle of eye


name: Elevated circulating apolipoprotein B concentration


name: Decreased circulating apolipoprotein A-I concentration


name: Elevated circulating apolipoprotein A-II concentration


name: Abnormal hypoxanthine-guanine phosphoribosyltransferase level


name: Elevated hypoxanthine-guanine phosphoribosyltransferase level


name: Reduced hypoxanthine-guanine phosphoribosyltransferase level


name: Abnormal circulating superoxide dismutase activity


name: Increased circulating superoxide dismutase concentration


name: Decreased circulating superoxide dismutase concentration


name: Abnormal circulating hepcidin concentration


name: Decreased circulating hepcidin concentration


name: Elevated circulating hepcidin concentration


name: Abnormal circulating selenium concentration


name: Anti-mitochondrial M2 antibody positivity


name: Focal hyperintensity of cerebral white matter on MRI


name: Multifocal hyperintensity of cerebral white matter on MRI


name: Confluent hyperintensity of cerebral white matter on MRI


name: Focal hypointensity of cerebral white matter on MRI


name: Multifocal hypointensity of cerebral white matter on MRI


name: Confluent hypointensity of cerebral white matter on MRI


name: Decreased level of 1,5 anhydroglucitol in serum


name: Increased level of 3-hydroxy-3-methylglutaric acid in urine


name: Elevated circulating gamma-aminobutyric acid concentration


name: Decreased circulating GABA concentration


name: Increased level of galactonate in red blood cells


name: Increased level of galactitol in red blood cells


name: Increased level of hippuric acid in blood


name: Increased level of hippuric acid in urine


name: Increased level of propylene glycol in blood


name: Increased level of L-pyroglutamic acid in urine


name: Abnormal circulating biotinidase concentration


name: Decreased circulating biotinidase concentration


name: Elevated circulating biotinidase concentration


name: Increased level of methylsuccinic acid in urine


name: Increased level of myristic acid in serum


name: Increased level of N-acetylneuraminic acid in urine


name: Increased level of N-acetylneuraminic acid in fibroblasts


name: Increased circulating troponin I concentration


name: Increased circulating troponin T concentration


name: Abnormal circulating glucose-6-phosphate dehydrogenase concentration


name: Abnormal glucose-6-phosphate dehydrogenase level in blood


name: Increased glucose-6-phosphate dehydrogenase level in blood


name: Decreased glucose-6-phosphate dehydrogenase level in blood


name: Abnormal glucose-6-phosphate dehydrogenase level in dried blood spot


name: Increased glucose-6-phosphate dehydrogenase level in dried blood spot


name: Decreased glucose-6-phosphate dehydrogenase level in dried blood spot


name: Abnormal glucose-6-phosphate dehydrogenase level in leukocytes


name: Abnormal glucose-6-phosphate dehydrogenase level in red blood cells


name: Abnormal glucose-6-phosphate dehydrogenase level in tissue


name: Increased glucose-6-phosphate dehydrogenase level in tissue


name: Decreased glucose-6-phosphate dehydrogenase level in tissue


name: Decreased glucose-6-phosphate dehydrogenase level in red blood cells


name: Increased glucose-6-phosphate dehydrogenase level in red blood cells


name: Decreased glucose-6-phosphate dehydrogenase level in leukocytes


name: Increased glucose-6-phosphate dehydrogenase level in leukocytes


name: Abnormal circulating UDP glucose-4-epimerase concentration


name: Increased circulating UDP glucose-4-epimerase concentration


name: Decreased circulating UDP glucose-4-epimerase concentration


name: Abnormal erythrocyte UDP glucose-4-epimerase concentration


name: Increased erythrocyte UDP glucose-4-epimerase concentration


name: Decreased erythrocyte UDP glucose-4-epimerase concentration


name: Abnormal natural killer subset distribution


name: Delayed canalization of nasolacrimal duct


name: syringe with needle,insulin 0.5 mL (half unit mark) 30 gauge X 5/16" MISCELL SYRINGE, EMPTY DISPOSABLE


name: OCTOCRYLENE 100 mg in 1 mL / TITANIUM DIOXIDE 41.5 mg in 1 mL / AVOBENZONE 35 mg in 1 mL / DROMETRIZOLE TRISILOXANE 30 mg in 1 mL / ECAMSULE 30 mg in 1 mL TOPICAL LOTION [Garnier Ombrelle SPF 60 Face Ultra Light]


name: HOMOSALATE 100 mg in 1 mL / OCTOCRYLENE 55 mg in 1 mL / octisalate 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / DROMETRIZOLE TRISILOXANE 25 mg in 1 mL / ECAMSULE 5 mg in 1 mL TOPICAL LOTION [Garnier Ombrelle SPF 30 Complete Lightweight]


name: HOMOSALATE 100 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL / octisalate 50 mg in 1 mL / AVOBENZONE 40 mg in 1 mL / DROMETRIZOLE TRISILOXANE 25 mg in 1 mL / ECAMSULE 5 mg in 1 mL TOPICAL LOTION [Garnier Ombrelle SPF 60 Complete Lightweight]


name: OCTINOXATE 2 mg in 1 mL TOPICAL CREAM [Cover Cream. Sun protection]


name: OCTINOXATE 2 g in 100 g / TITANIUM DIOXIDE 1.2 g in 100 g TOPICAL POWDER [ALMOST powder MAKEUP BROAD SPECTRUM SPF 18]


name: Medical Food Oral Suspension [PediaSure Sidekicks]


name: Assure ID 30G 3/16 inch Safety Pen Needle


name: Assure ID 30G 5/16 inch Safety Pen Needle


name: Assure ID 31G 3/16 inch Safety Pen Needle


name: Breathe Right Extra Strength Nasal Strip (Clear)


name: Breathe Right Extra Strength Nasal Strip (Tan)


name: CVS Series 400 Upper Arm Blood Pressure Monitor System


name: CVS Series 400W Wrist Blood Pressure Monitor


name: LAVARE Wound Wash Gel Base for Compounding


name: PediaSure SideKicks Enteral Shake (Chocolate)


name: PediaSure SideKicks Enteral Shake (Strawberry)


name: AVOBENZONE 3 g in 100 g / HOMOSALATE 9 g in 100 g / OCTISALATE 4.5 g in 100 g / OCTOCRYLENE 3 g in 100 g / OXYBENZONE 4.5 g in 100 g TOPICAL CREAM [TimeWise Age Minimize 3D Day Cream SPF 30 Broad Spectrum Sunscreen (Combo to Oily Skin)]


name: Mary Kay TimeWise Miracle Set 3D The Go Set (Combo to Oily Skin) KIT


name: Salt Stable LO Pharmaceutical Compounding Agent


name: Sanare Advanced Scar Therapy Base for Compounding


name: Versa Plus Sugarless Compounding Suspension Vehicle


name: OCTINOXATE 60 mg in 1 mL / OCTISALATE 20 mg in 1 mL / TITANIUM DIOXIDE 23.4 mg in 1 mL / ZINC OXIDE 38.4 mg in 1 mL TOPICAL CREAM [ERBORIAN CC RED CORRECT SPF 25]


name: OCTINOXATE 70 mg in 1 g / TITANIUM DIOXIDE 41.5 mg in 1 g / ZINC OXIDE 98 mg in 1 g TOPICAL EMULSION [CAPTURE DREAMSKIN FRESH AND PERFECT CUSHION WITH SUNSCREEN BROAD SPECTRUM SPF 50 000]


name: TITANIUM DIOXIDE 60 mg in 1 mL / ZINC OXIDE 60 mg in 1 mL TOPICAL CREAM [PURE HAVEN BODY SPF 30]


name: compounding vehicle syrup no.23 ORAL SYRUP


name: inhaler,assist device with large mask MISCELL SPACER (EA)


name: inhaler,assist device with medium mask MISCELL SPACER (EA)


name: inhaler,assist device with small mask MISCELL SPACER (EA)


name: multivitamin with minerals combination no.64


name: nutritional supplement 0.07 gram-1.5 kcal/mL ORAL LIQUID IN BAG, ENFIT (ML)


name: nutritional therapy, glucose intolerance


name: pen needle, diabetic, safety 30 gauge X 3/16" MISCELL NEEDLE, DISPOSABLE


name: pen needle, diabetic, safety 30 gauge X 5/16" MISCELL NEEDLE, DISPOSABLE


name: pen needle, diabetic, safety 31 gauge X 3/16" MISCELL NEEDLE, DISPOSABLE


name: skin cleanser combination no.41 TOPICAL CLEANSER (ML)


name: TITANIUM DIOXIDE 74 mg in 1 mL / ZINC OXIDE 63 mg in 1 mL TOPICAL CREAM [it cosmetics Your Skin But Better CC Plus Oil Free Matte Poreless Finish Full Coverage Broad Spectrum SPF 40 Sunscreen All Shades]


name: Titanium Dioxide 0.80 g in 13.32 g / Zinc Oxide 0.63 g in 13.32 g TOPICAL STICK [CeraVe Developed with Dermatologists Sunscreen Broad Spectrum SPF 50]


name: OCTINOXATE 75 mg in 1 g / ZINC OXIDE 105 mg in 1 g TOPICAL CREAM [CeraVe Developed with Dermatologists Skin Renewing Broad Spectrum SPF 30 Day]


name: BlueStar OTC Diabetes Self-Management Digital


name: Dexcom G6 Receiver Continuous Blood-Glucose M


name: PHENTOLAMINE MESYLATE 9.9 g in 10 g NOT APPLICABLE POWDER [AX Pharmaceutical Corp]


name: D-COL Personal Hygiene Convenience kit KIT


name: HOMOSALATE 15 g in 100 g / OCTISALATE 5 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL SPRAY [SPF 70 Sunscreen]


name: TITANIUM DIOXIDE 90 mg in 1 mL / ZINC OXIDE 63 mg in 1 mL TOPICAL CREAM [it cosmetics Your Skin But Better CC Plus Illumination Color Correcting Illuminating Broad Spectrum SPF 50 Plus Sunscreen Full Coverage FairLight NeutralTan RichHoney LightMedium and NeutralMedium]


name: Adenosine 0.04 g in 100 mL TOPICAL CREAM [VIVA]


name: Lidocaine Hydrochloride 2% Oromucosal Solution [Medicated Buccal DNA Collection Kit]


name: influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen / influenza B virus B/Maryland/15/2016 antigen / influenza B virus B/Phuket/3073/2013 antigen


name: {1 (118 ML) (benzoyl peroxide 25 MG/ML Medicated Liquid Soap) / 1 (59 ML) (benzoyl peroxide 37 MG/ML Topical Lotion) } Pack


name: {1 (59 ML) (benzoyl peroxide 100 MG/ML Topical Lotion) / 1 (118 ML) (benzoyl peroxide 25 MG/ML Medicated Liquid Soap) } Pack


name: ADAPTER,FEEDING,14F ENFIT HALYARD #8135-14


name: ADAPTER,FEEDING,20F ENFIT HALYARD #8135-20


name: ADAPTER,FEEDING,24F ENFIT HALYARD #8135-24


name: DRESSING,AQUACEL AG FOAM ADHESIVE 3.25IN X 3.25IN #420805


name: VAD DRIVELINE MAINTENANCE KIT CENTURION #DM815


name: Lidocaine Hydrochloride 2% Oromucosal Solution [Medicated Buccal DNA Collection Kit 2]


name: Differin Oil Control Moisturizer with SPF30


name: SimplyThick Gel Individual Serving Packets, H


name: SimplyThick Gel Individual Serving Packets, N


name: {84 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack [Iclevia 91 Day]


name: Avobenzone 3 g in 100 mL / Octisalate 5 g in 100 mL / Octocrylene 7 g in 100 mL TOPICAL LOTION [Differin Oil Absorbing Moisturizer SPF 30]


name: DIMETHICONE 0.53 g in 50 mL / NIACINAMIDE 1 g in 50 mL / ADENOSINE 0.02 g in 50 mL TOPICAL CREAM [AQUTOP Moisturizing Signature Tone-up Cream]


name: ADENOSINE 0.012 g in 30 g TOPICAL PATCH [LOVELY GERANIUM AROMATHERAPY MASK 30g]


name: NIACINAMIDE 0.54 g in 27 g TOPICAL PATCH [FRESH MANDARIN AROMATHERAPY MASK 27g]


name: TITANIUM DIOXIDE 6.5 g in 100 g TOPICAL LOTION [LA MER THE LUMINOUS LIFTING CUSHION FOUNDATION BROAD SPECTRUM SPF 20]


name: OCTINOXATE 75 mg in 1 mL / ZINC OXIDE 73 mg in 1 mL TOPICAL LOTION [Journee Bio-restorative Day Balm Broad-spectrum Suncreen SPF 30]


name: Titanium Dioxide 4.01 g in 50 mL / Octinoxate 2.50 g in 50 mL / Zinc Oxide 1.50 g in 50 mL TOPICAL CREAM [MIZON SNAIL REPAIR BLEMISH BALM ROSE BEIGE]


name: Adenosine 0.01 g in 25 mL TOPICAL CREAM [MIZON COLLAGEN POWER FIRMING EYE CREA M]


name: Adenosine 0.012 g in 30 mL TOPICAL LIQUID [MIZON HYALURONIC ACID 100]


name: Adenosine 0.018 g in 45 mL TOPICAL CREAM [MIZON SNAIL RECOVERY GE L CREA M]


name: Adenosine 0.02 g in 50 mL TOPICAL CREAM [MIZON COLLAGEN POWER FIRMING ENRICHED CREA M]


name: Mineral Oil 327.54 g in 410 mL TOPICAL OIL [MIZON NO.1 KINGSBERRY CLEANSING OI L]


name: Niacinamide 0.60 g in 30 mL / Adenosine 0.012 g in 30 mL TOPICAL LIQUID [MIZON SNAIL REPAIR INTENSIVE AMPOULE]


name: Niacinamide 1.50 g in 75 mL / Adenosine 0.03 g in 75 mL TOPICAL CREAM [MIZON BLACK SNAIL ALL IN ONE CREA M]


name: Isopropyl Alcohol;Lidocaine Hydrochloride;Methylprednisolone Acetate 70%; 1%; 40 MG/1 ML Multiple Routes Kit [Point of Care L.2]


name: PIMOBENDAN 495 g in 500 g NOT APPLICABLE POWDER [AX Pharmaceutical Corp]


name: PONAZURIL 495 g in 500 g NOT APPLICABLE POWDER [AX Pharmaceutical Corp]


name: Capsaicin/Menthol/Methyl Salicylate;Diclofenac Sodium 0.025%-6%-25%; 1.5% Topical application Solution


name: SILICON DIOXIDE 13.0 g in 100 g / PYRIDOXINE HYDROCHLORIDE 0.05 g in 100 g TOPICAL PASTE, DENTIFRICE [Dr.Pauhls TOOTHPAST E LIME MANDARIN FLAVOR]


name: WITCH HAZEL 0.098 g in 100 mL / CAFFEINE 0.01 g in 100 mL TOPICAL CREAM [Powerbooster Original]


name: WITCH HAZEL 0.098 g in 100 mL / MENTHOL 0.1 g in 100 mL / CAFFEINE 0.05 g in 100 mL TOPICAL CREAM [Powerbooster Mild]


name: Adenosine 0.012 g in 30 mL TOPICAL LIQUID [MIZON PEPTIDE 500]


name: Adenosine 0.02 g in 50 mL TOPICAL CREAM [MIZON PEPTIDE AMPOULE CREA M]


name: Adenosine 0.03 g in 75 mL TOPICAL CREAM [MIZON ALL IN ONE SNAIL REPAIR CREA M]


name: Mineral Oil 7.26 g in 10 mL / Octinoxate 0.40 g in 10 mL TOPICAL LIQUID [MIZON COLLAGENIC AQUA VOLUME UP LI P ESSENCE RENEWAL]


name: Nurses Improving Care for Health System Elders


name: Calcitonin Gene-Related Peptide Receptor Antagonists


name: Extended Focused Assessment with Sonography for Trauma


name: Look-Alike Sound-Alike Drug Substitution Errors


name: boswellic acid, curcumin, and valeric acid extract


name: Federal Employee Health Plan - Use when known


name: Self-pay (Includes applicants for insurance and Medicaid applicants)


name: Ultrasonography of chest and bilateral axillae


name: Ultrasonography of chest and left axilla


name: Ultrasonography of chest and right axilla


name: Carrier of extended spectrum beta-lactamase producing bacteria


name: Fagerstrom Test for Nicotine Dependence total score


name: Assessment using Fagerstrom Test for Nicotine Dependence


name: New York Heart Association Classification class


name: Assessment using New York Heart Association Classification


name: Malignant neoplasm of intestine suspected


name: Assessment using Framingham coronary heart disease 10 year risk score


name: University of Texas Wound Classification System


name: University of Texas Wound Classification System grade


name: University of Texas Wound Classification System stage


name: Assessment using University of Texas Wound Classification System


name: Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score


name: CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score


name: History of infertility due to endometriosis


name: History of female infertility due to tubal factor


name: Antenatal thalassemia screening declined


name: Antenatal screening for viral hepatitis type B declined


name: Antenatal screening for human immunodeficiency virus declined


name: Assessment using Hamilton Rating Scale for Depression


name: Assessment using Cardiovascular Limitations and Symptoms Profile


name: Assessment using Asthma Control Questionnaire


name: Creation of mold for custom made foot orthosis


name: Repair of epispadias urethroplasty using glanular flap


name: Repair of hypospadias urethroplasty using glanular flap


name: Repair of recurrent ventral hernia using insert of prosthetic material


name: Repair of recurrent ventral hernia using sutures


name: Repair of recurrent ventral hernia using insert of natural material


name: European System for Cardiac Operative Risk Evaluation score


name: Assessment using Christo Inventory for Substance-misuse Services


name: Assessment using Pittsburgh Sleep Quality Index


name: Assessment using ICIQ-UI-SF (International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form)


name: Assessment using Footwear Suitability Scale


name: Assessment using FINDRISC (Finnish Diabetes Risk Score)


name: Assessment using New Zealand priority criteria for major joint replacement


name: Assessment using DLQI (Dermatology Life Quality Index)


name: Assessment using TYM (Test Your Memory) test


name: Assessment using I-PSS (International Prostate Symptom Score)


name: Program of study for child with special needs


name: Assessment using Leeds Foot Impact Scale


name: DLQI (Dermatology Life Quality Index) score


name: Cannabinoid receptor agonist (disposition)


name: Fluoroscopy guided intrathecal injection of anesthetic


name: Assessment using PEDIS (Perfusion, Extent, Depth, Infection and Sensation) scoring system


name: Assessment using ESS (Epworth Sleepiness Scale)


name: Assessment using CSHA (Canadian Study of Health and Aging) Clinical Frailty Scale


name: Assessment using Canadian Cardiovascular Society grading of angina pectoris


name: Assessment using Patient Global Impression of Improvement


name: Assessment using Manchester Scale for grading hallux valgus


name: Assessment using BASMI (Bath Ankylosing Spondylitis Metrology Index)


name: Assessment using SADQ (Severity of Alcohol Dependence Questionnaire)


name: Patient Global Impression of Improvement


name: DEPA (Depth, Extent, Phase and Associated etiology) Score


name: MIPI - Mantle Cell Lymphoma International Prognostic Index


name: PEDIS (Perfusion, Extent, Depth, Infection and Sensation) scoring system


name: Assessment using DEPA (Depth, Extent, Phase and Associated etiology) Score


name: Manchester Scale for grading hallux valgus


name: Assessment using Anticholinergic Cognitive Burden Scale


name: Assessment using QRISK cardiovascular disease 10 year risk calculator


name: QRISK cardiovascular disease 10 year risk calculator score


name: QRISK2 cardiovascular disease 10 year risk calculator


name: Mental health care program approach contingency plan


name: Excision of pilonidal sinus and closure with skin flap


name: PEDIS (Perfusion, Extent, Depth, Infection and Sensation) scoring system score


name: AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) score


name: CAGE (Cutting down, Annoyance by criticism, Guilty feeling and Eye-openers) Questionnaire total score


name: SINBAD (Site, Ischemia, Neuropathy, Bacterial Infection and Depth) classification total score


name: Patient Global Impression of Improvement score


name: Manchester Scale for grading hallux valgus score


name: Canadian Cardiovascular Society grading of angina pectoris grade


name: CSHA (Canadian Study of Health and Aging) Clinical Frailty Scale score


name: MADRS (Montgomery-Asberg Depression Rating Scale) score


name: Repair of left cleft lip using straight line technique


name: Repair of right cleft lip using straight line technique


name: Size (area, depth), Sepsis, Arteriopathy, Denervation system


name: Assessment using Manchester-Oxford Foot Questionnaire (foot and ankle)


name: MOxFQ (Manchester-Oxford Foot Questionnaire) (foot) Summary Index score


name: Assessment using GPCOG (General Practitioner assessment of Cognition)


name: S(AD) SAD (Size (area, depth) Sepsis, Arteriopathy, Denervation) system score


name: MOxFQ (Manchester-Oxford Foot Questionnaire) (foot)


name: MOxFQ (Manchester-Oxford Foot Questionnaire) (foot and ankle) Summary Index score


name: MOxFQ (Manchester-Oxford Foot Questionnaire) (foot and ankle)


name: Assessment using MOxFQ (Manchester-Oxford Foot Questionnaire) (foot)


name: Assessment using AUDIT-C (Alcohol Use Disorders Identification Test - Consumption)


name: Assessment using CAGE (Cutting down, Annoyance by criticism, Guilty feeling and Eye-openers) Questionnaire


name: Assessment using SINBAD (Site, Ischemia, Neuropathy, Bacterial Infection, Area and Depth) classification


name: Assessment using S(AD) SAD (Size (area, depth) Sepsis, Arteriopathy, Denervation) system


name: Provision of prefabricated pneumatic walking brace


name: Mental health care program approach crisis plan


name: Repair of left cleft lip with triangular flap


name: Repair of right cleft lip with triangular flap


name: Repair of left cleft lip with rotation advancement flap


name: Repair of right cleft lip with rotation advancement flap


name: Autologous adipose tissue injection syringe


name: Peripheral vascular graft extraluminal mesh-sleeve


name: Intraoperative insertion of cardiac pacemaker


name: Assessment using patient satisfaction score


name: Antenatal screening for Down, Edwards and Patau syndromes declined


name: Antenatal screening for Down syndrome declined


name: Antenatal screening for Edwards and Patau syndromes declined


name: Fluoroscopic venography of basilic vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of axillary vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of brachial vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of cephalic vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of common femoral vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of superficial forearm vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of iliac vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of innominate vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of mesenteric vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of popliteal vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of renal vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of subclavian vein using contrast with insertion of metallic stent graft


name: Fluoroscopic venography of superficial femoral vein using contrast with insertion of metallic stent graft


name: Monitoring of hormone replacement therapy


name: Monitoring of hormone replacement therapy declined


name: Optical-guidance prostate biopsy system handpiece and needle


name: Respiratory oxygen therapy monitor and regulator


name: Tuberculin and allergy syringe and non-retractable needle


name: Family history of intellectual disability


name: Assessment using EMS (Elderly Mobility Scale)


name: Assessment using Mini AQLQ (Asthma Quality of Life Questionnaire)


name: Mini AQLQ (Asthma Quality of Life Questionnaire) score


name: Assessment using Clinical Opiate Withdrawal Scale


name: Fluoroscopy guided percutaneous transluminal angioplasty of coronary artery with contrast using drug eluting balloon catheter


name: Refusal by patient to provide information about ethnic group


name: Medicinal product categorized by structure


name: Provision of patient held diabetes record declined


name: Provision of patient held diabetes record


name: Radionuclide imaging using iobenguane (131-I)


name: Bilateral lower limb pain at rest due to atherosclerosis


name: Thrombolysis of cerebral artery by intravenous infusion


name: Radionuclide imaging of whole body using Iobenguane (123-I)


name: Collection of blood via implanted venous access device


name: Image guided endovascular insertion of inferior vena cava filter


name: Refusal by patient to provide information about religion


name: Antineoplastic chemotherapy regimen declined


name: Radionuclide imaging of thyroid using technetium (99m-Tc) sodium pertechnetate


name: Radionuclide imaging of thyroid using iodine-125


name: Radionuclide imaging of thyroid using technetium-99m


name: Radionuclide imaging using chromium-51 labeled erythrocytes


name: Substance with sigma-1 receptor agonist mechanism of action


name: Sigma-1 receptor agonist-containing product


name: Aortic arch endovascular stent-graft extender


name: Oropharyngeal mucosal probiotic dressing


name: History of amputation of bilateral lesser toes


name: Administration of adult hepatitis A vaccine


name: Administration of inactivated Japanese encephalitis virus adsorbed vaccine via intramuscular route


name: Administration of live attenuated measles, mumps, and rubella vaccine


name: Administration of live attenuated measles and mumps and rubella and varicella-zoster vaccine


name: Administration of intramuscular inactivated Japanese encephalitis vaccine


name: Administration of diphtheria and hepatitis B and acellular pertussis and inactivated poliomyelitis and tetanus vaccine


name: Administration of heat treated rabies immune globulin


name: History of ureteral stent previously removed


name: Administration of diphtheria and tetanus vaccine, less than 7 years of age


name: Removal of joint prosthesis for periprosthetic joint infection


name: Measurement of iodine radioisotope in plasma


name: Interleukin-4 receptor alpha antagonist-containing product


name: Administration of meningococcus A, C, W135 and Y capsular oligosaccharide conjugated vaccine


name: Administration of pentavalent live attenuated rotavirus vaccine via oral route


name: Radionuclide imaging of myocardium using technetium (99m-Tc) pyrophosphate


name: Refusal by patient to provide information about spoken language


name: Assessment using Salford Rheumatoid Arthritis Foot Evaluation Instrument


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument


name: Magnetic resonance imaging of coccygeal spine


name: MRI with contrast for radiotherapy planning


name: Magnetic resonance imaging for radiotherapy planning


name: Fluoroscopy guided percutaneous transluminal coil embolization of arteriovenous fistula with contrast


name: Substance with gamma-aminobutyric acid A receptor agonist mechanism of action


name: Radionuclide imaging of thyroid using technetium (99m-Tc) succimer


name: Fluoroscopy guided removal of nephrostomy tube from transplanted kidney


name: PET CT of whole body using fluoromisonidazole (18-F)


name: PET CT of whole body using fluorothymidine (18-F)


name: PET CT of brain using fluorodexoxyglucose (18-F)


name: Positron emission tomography of brain using fluorodopa (18-F)


name: Positron emission tomography of brain using Fluorocholine (18-F)


name: Radionuclide imaging using radioisotope labeled leukocytes


name: Radionuclide imaging using samarium (153-Sm) lexidronam


name: Selective internal radiotherapy of liver using yttrium (90-Y) labeled microspheres


name: Positron emission tomography of whole body using choline C-11


name: Positron emission tomography with computed tomography of whole body using choline C-11


name: Doppler ultrasonography compression venography of lower limb


name: Positron emission tomography of whole body using fluorocholine (18-F)


name: Positron emission tomography with computed tomography of whole body using fluorocholine (18-F)


name: Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate


name: Positron emission tomography of whole body using gallium (68-Ga) dotatate


name: PET CT of whole body using 18F fluciclovine


name: Positron emission tomography and computed tomography of whole body using methionine C-11


name: Positron emission tomography of whole body using methionine C-11


name: Positron emission tomography using methionine C-11


name: Positron emission tomography with computed tomography using methionine C-11


name: Doppler ultrasonography guided marking of skin over long saphenous vein


name: Doppler ultrasonography guided marking of skin over small saphenous vein


name: CT guided percutaneous irreversible electroporation of neoplasm of pancreas


name: Neonatal hypothermia cot heat-retention pad


name: Left-ventricular wireless pacing system transducer and electrode


name: Left-ventricular wireless pacing system sensor and transmitter


name: Neonatal hypothermia cot heat-conduction mattress


name: Conventional release and prolonged-release oral tablet


name: Conventional release and prolonged-release


name: Transplant recipient EBV (Epstein Barr virus) antibody negative


name: Radionuclide imaging using lilotomab satetraxetan (177-Lu)


name: Transplant donor EBV (Epstein Barr virus) antibody negative


name: Transplant recipient EBV (Epstein Barr virus) antibody positive


name: Transplant donor EBV (Epstein Barr virus) antibody positive


name: Psychologically prepared to undergo surgery


name: Positron emission tomography with computed tomography of whole body using gallium-68


name: GSPECT of myocardium using technetium (99m-Tc) sestamibi


name: Radionuclide imaging of myocardium using technetium (99m-Tc) sestamibi with cardiac stress test


name: Radionuclide imaging of myocardium using technetium (99m-Tc) sestamibi with administration of dipyridamole


name: Operative procedure canceled before anesthesia start time


name: Operative procedure canceled before time of induction of anesthesia


name: Operative procedure canceled after time of induction of anesthesia


name: Dopa decarboxylase inhibitor-containing product


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part A: Fixed Scale - Footwear total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part A: Fixed Scale - Disability total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Personal feelings domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Impact on career domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Effect on family life domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - External factors that affect foot symptoms domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Visual impact domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part A: Fixed Scale - Impairment total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Impact on everyday functioning domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Experiences with footwear domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Impact on social life domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Personal adaptation domain total score


name: Salford Rheumatoid Arthritis Foot Evaluation Instrument Part B: Patient Preference Scale - Foot and Ankle Symptoms domain total score


name: Radionuclide imaging of adrenal gland using iobenguane (123-I)


name: Hypogastric plexus block using fluoroscopic guidance


name: Ganglion impar block using fluoroscopic guidance


name: Fluoroscopic guided thoracic sympathetic plexus block


name: Stellate ganglion block using fluoroscopic guidance


name: Obturator nerve block using fluoroscopic guidance


name: Lumbar sympathetic plexus block using fluoroscopic guidance


name: Open repair of obstructed ventral hernia


name: Open repair of obstructed ventral hernia with prosthesis


name: Open repair of strangulated ventral hernia


name: Open repair of strangulated ventral hernia with prosthesis


name: Revision of one component of total prosthetic replacement of knee joint not using cement


name: Revision of one component of total prosthetic replacement of knee joint using cement


name: Fluoroscopy guided percutaneous transluminal chemoembolization of hepatic artery with contrast


name: Consent given for therapeutic procedure to be carried out by student


name: Retrospectively electrocardiogram gated computed tomography angiography of coronary artery with contrast


name: Three dimensional ultrasonography of abdominal aortic endovascular aneurysm repair with contrast


name: 24 hour radionuclide imaging of whole body using radioisotope labeled human immunoglobulin G


name: Angiography of cervical portion of left internal carotid artery


name: Angiography of cervical portion of right internal carotid artery


name: Monitoring of smoking cessation therapy declined


name: Radionuclide imaging using iodine (131-I) labeled monoclonal antibody


name: Radionuclide imaging using indium (111-In) labeled monoclonal antibody


name: Radionuclide imaging using radioisotope labeled monoclonal antibody


name: Radionuclide imaging using oleic acid (125-I)


name: Angiography of left cervical vertebral artery


name: Angiography of right cervical vertebral artery


name: Angiography of right coronary artery bypass graft


name: Angiography of left coronary artery bypass graft


name: Prospectively electrocardiogram gated computed tomography angiography of coronary artery with contrast


name: DTSQs (Diabetes Treatment Satisfaction Questionnaire status version) score


name: Assessment using DTSQs (Diabetes Treatment Satisfaction Questionnaire status version)


name: Doppler ultrasonography compression venography of upper limb


name: Pocock death from cardiovascular disease risk score


name: Assessment using Pocock death from cardiovascular disease risk score


name: Computer aided speech and language therapy


name: Fluoroscopy guided removal of implantable venous access device


name: Doppler ultrasonography of vascular structure of hand


name: Dynamic radionuclide imaging of liver using radioisotope


name: Static radionuclide imaging of liver using radioisotope


name: Radionuclide imaging of liver using rose bengal (131-I) sodium


name: Dynamic radionuclide imaging of liver and spleen using technetium (99m-Tc)


name: Dynamic radionuclide imaging of liver using technetium (99m-Tc)


name: Sexually attracted to male and female sex


name: Sexually attracted to neither male nor female sex


name: Sexual relationship problem due to gender identity confusion


name: Radionuclide imaging using technetium (99m-Tc) exametazime with cerebral blood flow


name: Radionuclide imaging using radioisotope with cerebral blood flow


name: Radionuclide imaging using technetium (99m-Tc) human serum albumin with cerebral blood flow


name: Static radionuclide imaging of spleen using technetium (99m-Tc)


name: Dynamic radionuclide imaging of spleen using technetium (99m-Tc)


name: Static radionuclide imaging of liver and spleen using technetium (99m-Tc)


name: Radionuclide imaging of esophagus using technetium (99m-Tc) sucralfate


name: Radionuclide imaging of kidney using technetium (99m-Tc) pentavalent succimer for renal neoplasm


name: Radionuclide imaging of hematopoietic system using iron radioisotope


name: Selective beta-3 agonist-containing product


name: Dual isotope single photon emission computed tomography of parathyroid using technetium-99m and thallium-201


name: Substance with farnesoid X receptor agonist mechanism of action


name: Single photon emission computed tomography using technetium (99m-Tc) sulesomab


name: Dual isotope single photon emission computed tomography with computed tomography of parathyroid using technetium-99m and thallium-201


name: SPECT CT of bone of ankle using 186-Re (rhenium-186)


name: SPECT of bone of ankle using 186-Re (rhenium-186)


name: SPECT of bone of elbow using 186-Re (rhenium-186)


name: SPECT of bone of knee using 186-Re (rhenium-186)


name: SPECT CT of bone of elbow using 186-Re (rhenium-186)


name: SPECT CT of bone of knee using 186-Re (rhenium-186)


name: History of primary malignant neoplasm of skin


name: Sexual relationship problem due to sexual orientation confusion


name: Uses home continuous positive airway pressure ventilation supply


name: Radionuclide imaging of whole body using gallium-67 for localization of inflammation


name: Radionuclide imaging using technetium (99m-Tc) labeled granulocytes with leukocyte phagocytosis test


name: Radionuclide imaging using technetium (99m-Tc) sulesomab


name: Percutaneous cryotherapy of neoplasm of left kidney


name: Percutaneous cryotherapy of neoplasm of right kidney


name: Closure of urethral fistula with preputial flap


name: Radionuclide imaging of whole body using iodine-131 for localization of neoplasm


name: Radionuclide imaging of whole body using iobenguane (131-I)


name: Radionuclide imaging of whole body using iobenguane (131-I) for localization of neoplasm


name: Radionuclide imaging using Indium (111-In) labeled mixed leukocyte


name: Radionuclide imaging of parathyroid using technetium (99m-Tc) and thallium-201


name: Normal lower limb movement and sensation and circulation


name: Normal upper limb movement and sensation and circulation


name: Gastro-resistant and prolonged-release oral granules


name: Insertion of silicone breast implant into left breast


name: Insertion of silicone breast implant into right breast


name: Difficult supraglottic airway ventilation


name: Substance with dopamine receptor D2 antagonist mechanism of action


name: Dopamine receptor D2 antagonist-containing product


name: Radionuclide imaging using high dose gallium-67


name: Drug-eluting urethral dilatation catheter


name: Movement-resistance gait rehabilitation device


name: Electroporation therapy system endoscopic applicator


name: Plastic and/or related compound (substance)


name: Substance with nicotinic receptor antagonist mechanism of action


name: Genetic hyperferritinemia without iron overload


name: Medicinal product categorized by disposition


name: Calcium-sensing receptor activator (disposition)


name: Medicinal product categorized by chemical element


name: Substance with progesterone receptor antagonist mechanism of action


name: Glucocorticoid receptor antagonist (disposition)


name: Substance with glucocorticoid receptor antagonist mechanism of action


name: lymphangiography of left upper extremity


name: Administration of diphtheria and acellular pertussis and inactivated poliomyelitis and tetanus vaccine


name: Family history of double heterozygous familial hypercholesterolemia


name: lymphangiography of right upper extremity


name: lymphangiography of left lower extremity


name: lymphangiography of right lower extremity


name: Radionuclide imaging of hepatobiliary structure using radioisotope labeled cholecystokinin


name: Revision of posterior fusion of atlantoaxial joint


name: Product manufactured as cutaneous dose form


name: Product manufactured as transdermal dose form


name: Product manufactured as urethral dose form


name: Product manufactured as dental dose form


name: Product manufactured as endocervical dose form


name: Product manufactured as enteral dose form


name: Product manufactured as gingival dose form


name: Product manufactured as oromucosal dose form


name: Product manufactured as pulmonary dose form


name: Excision of entire left testis by inguinal approach


name: Excision of entire right testis by inguinal approach


name: Excision of entire right testis by scrotal approach


name: Excision of entire left undescended testis


name: Excision of entire right undescended testis


name: Surgical reduction of torsion of left testis with fixation of right testis


name: Surgical reduction of torsion of right testis with fixation of left testis


name: Evacuated blood collection tube with heparin sodium


name: Evacuated blood collection tube with clot activator


name: Evacuated blood collection tube with citrate and theophylline and adenosine and dipyramidole


name: Evacuated blood collection tube with tripotassium and ethylene diamine tetraacetic acid and aprotinin


name: Evacuated blood collection tube with heparin lithium and gel separator


name: Limited life expectancy of approximately one year


name: Norepinephrine reuptake inhibitor and serotonin reuptake inhibitor


name: Gamma-aminobutyric acid receptor agonist-containing product


name: Operation on parathyroid gland during thyroidectomy


name: Speech therapy for compensatory articulation


name: Exercise induced moderate microalbuminuria


name: Radionuclide measurement of leakage during isolated limb perfusion using technetium (99m-Tc) labeled erythrocytes


name: Total abdominal hysterectomy using intrafascial technique


name: Total hysterectomy via vaginal approach using intrafascial technique


name: Ethanolamine and/or ethanolamine derivative-containing product


name: Administration of Varicella-zoster vaccine


name: Evacuated blood collection tube with sodium fluoride


name: Remote control insulin infusion patch pump blood glucose analyzer


name: Transcatheter heart valve prosthesis implantation catheter


name: Emergency airway clearance suction plunger


name: Mechanical positive pressure airway secretion-clearing device sensor


name: Beta-2 adrenergic receptor antagonist (disposition)


name: Deep impinging overbite with soft tissue destruction


name: Branching hyphae of kingdom Fungi detected


name: Nonbranching hyphae of kingdom Fungi detected


name: Broad irregular hyphae of kingdom Fungi detected


name: Revision of one component of total prosthetic replacement of hip joint not using cement


name: Calcium- and risedronic acid-containing product


name: Supervision of exercise therapy by healthcare professional


name: Finding of presence of dermatophyte hyphae and spores inside of hair shaft


name: Finding of presence of dermatophyte hyphae and spores outside of hair shaft


name: Nicotinic receptor antagonist-containing product


name: Ethylenediamine and/or ethylenediamine derivative-containing product


name: Progesterone receptor antagonist-containing product


name: Glucocorticoid receptor antagonist-containing product


name: Education about postoperative care after adenotonsillectomy


name: Accidental awareness under general anesthesia


name: Posterior crossbite limited to right side


name: Posterior crossbite limited to left side


name: Revision of one component of total prosthetic replacement of hip joint using cement


name: Revision of total prosthetic replacement of shoulder joint not using cement


name: Revision of one component of total prosthetic replacement of shoulder joint not using cement


name: Revision of hybrid prosthetic replacement of hip joint using cemented acetabular component


name: Revision of one component of total prosthetic replacement of shoulder joint using cement


name: Psychologically ready to undergo procedure


name: Anterior crossbite with destruction of oral mucosa


name: Radionuclide imaging of brain using technetium (99m-Tc) pentetic acid


name: Endoscopic insertion of pH monitoring capsule into esophagus


name: Full restoration of crown of tooth needed due to previous endodontic treatment


name: Height of alveolar bone surrounding teeth


name: Height of alveolar bone surrounding tooth


name: Yeast not Candida albicans and not Cryptococcus species detected


name: Yeast not Candida species and not Cryptococcus species detected


name: Finding of presence of double wall broad base budding yeast


name: Finding of presence of multiple budding yeast


name: Yeast not Cryptococcus gattii and not Cryptococcus neoformans detected


name: Full restoration of crown of tooth needed due to large tooth restoration


name: Finding of presence of unicellular fungus


name: Electrolytic-plasma endoscopic electrosurgical electrode


name: Spinal needle bio-impedence navigation unit


name: Silicone gel-filled smooth breast implant


name: Silicone gel-filled textured breast implant


name: Urine novel psychoactive substance detected


name: Urine novel psychoactive substance not detected


name: Excess of anterior part of lower alveolar ridge


name: Deficiency of anterior part of lower alveolar ridge


name: Deficiency of posterior part of lower alveolar ridge


name: Excess of posterior part of lower alveolar ridge


name: Intracellular elementary bodies of virus detected


name: World Health Organization Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale


name: Collection of body fluid from surgical drain


name: space maintainer - removable - bilateral, maxillary


name: certified translation or sign-language services - per visit


name: occlusal guard - hard appliance, partial arch


name: occlusal guard - soft appliance, full arch


name: occlusal guard - hard appliance, full arch


name: infiltration of sustained release therapeutic drug, per quadrant


name: temporomandibular joint dysfunction - non-invasive physical therapies


name: add metal substructure to acrylic full denture (per arch)


name: removable unilateral partial denture - one piece cast metal (including rententive/clasping materias, rests, and teeth), mandibular


name: removable unilateral partial denture - one piece cast metal (including retentive/clasping materials, rests, and teeth), maxillary


name: space maintainer - removable - bilateral, mandibular


name: space maintainer - fixed - bilateral, mandibular


name: space maintainer - fixed - bilateral, maxillary


name: blood glucose level test - in-office using a glucose meter


name: Cytomegalovirus DNA Terminase Complex Inhibitor


name: Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]


name: Interleukin-5 Receptor alpha-directed Cytolytic Antibody


name: Mechanical Ventilation Management: Pneumonia Prevention


name: Teaching: Toddler Nutrition 13-18 Months


name: Teaching: Toddler Nutrition 19-24 Months


name: Teaching: Toddler Nutrition 25-36 Months


name: Ultrasonography: Obstetric and Gynecologic


name: Identify when explanation of cause of injury is inconsistent among those involved


name: Determine expectations adult has for child to determine whether expected behaviors are realistic


name: Identify crisis situations that may trigger abuse (e.g., poverty, unemployment, divorce, homelessness, domestic violence)


name: Identify infants and children with high-care needs (e.g., prematurity, low birth weight, colic, feeding intolerances, major health problems in the first year of life, developmental disabilities, hyperactivity, attention deficit disorders)


name: Determine whether a child demonstrates signs of physical abuse (e.g., numerous injuries, unexplained bruises and welts, burns, fractures, unexplained facial lacerations and abrasions, human bite marks, whiplash, shaken infant syndrome)


name: Determine whether the child demonstrates signs of neglect (e.g., failure to thrive, wasting of subcutaneous tissue, consistent hunger, poor hygiene, constant fatigue and listlessness, skin afflictions, apathy, unyielding body posture, inappropriate dress for weather conditions)


name: Determine whether the child demonstrates signs of sexual abuse (e.g., difficulty walking or sitting, torn or bloody underclothing, reddened or traumatized genitals, vaginal or anal lacerations, recurrent urinary tract infections, poor sphincter tone, acquired sexually transmitted diseases, pregnancy, promiscuous behavior, history of running away)


name: Determine whether the child demonstrates signs of emotional abuse (e.g., lags in physical development, habit disorders, conduct learning disorders, neurotic traits or psychoneurotic reactions, behavioral extremes, cognitive developmental lags, attempted suicide)


name: Determine whether parents have unrealistic expectations or negative attributions for their child's behavior


name: Monitor for a progressive deterioration in the physical and emotional state of the infant or child


name: Determine parent's knowledge of basic care needs and provide appropriate childcare information, as indicated


name: Provide parents and their adolescents with information on decision-making and communication skills, and refer to youth services counseling, as appropriate


name: Provide parents with community resource information (e.g., addresses and phone numbers of agencies that provide respite care, emergency child care, housing assistance, substance abuse treatment, sliding-fee counseling services, food pantries, clothing distribution centers, domestic abuse shelters)


name: Screen for symptoms of a history of domestic abuse (e.g., numerous accidental injuries, multiple somatic symptoms, chronic abdominal pain, chronic headaches, pelvic pain, anxiety, depression, posttraumatic stress syndrome, and other psychiatric disorders)


name: Monitor for signs and symptoms of physical abuse (e.g., numerous injuries in various stages of healing; unexplained lacerations, bruises or welts, patches of missing hair, restraining marks on wrists or ankles, "defensive" bruises on forearms, human bite marks)


name: Monitor for signs and symptoms of sexual abuse (e.g., presence of semen or dried blood, injury to external genital, acquired sexually transmitted diseases,or dramatic behavioral or health changes of an undetermined etiology)


name: Monitor for signs and symptoms of exploitation (e.g., inadequate provision for basic needs when adequate resources are available; deprivation of personal possessions; unexplained loss of social support checks; lack of knowledge of personal finances or legal matters)


name: Interview patient or knowledgeable other about suspected abuse in the absence of partner


name: Monitor partner interactions and record observations, as appropriate (e.g., record times and duration of partner visits during hospitalization, underreactions or overreactions by partner)


name: Monitor for progressive deterioration in the physical and emotional state of individuals


name: Encourage expression of concerns and feelings, which may include fear, guilt, embarrassment, and self-blame


name: Identify elder patients who perceive themselves to be dependent on caretakers due to impaired health status, limited economic resources, depression, substance abuse, or lack of knowledge of available resources and alternatives for care


name: Identify family crisis situations that may trigger abuse (e.g., poverty, unemployment, divorce, homelessness, death of a loved one)


name: Identify caretakers who demonstrate impaired physical or mental health (e.g., substance abuse, depression, fatigue, back injuries due to unassisted lifting, injuries that were inflicted by patient); financial problems or dependency; failure to understand patient's condition or needs; intolerant or hypercritical attitudes toward patient; burnout; or those who threaten patient with abandonment, hospitalization, institutionalization, or painful procedures


name: Identify caretaker explanations of patient's injuries that are improbable, inconsistent, allege self-injury, blame others, include activities beyond elder's physical abilities, or demonstrate a delay in seeking treatment


name: Determine whether elder patient demonstrates signs of physical abuse (e.g., numerous injuries in various stages of healing; unexplained lacerations, abrasions, bruises, burns or fractures; patches of missing hair; human bite marks)


name: Determine whether the elder patient demonstrates signs of neglect (e.g., poor hygiene, inadequate or inappropriate clothing, untreated skin lesions, contractures, malnutrition, inadequate aids to mobility and perception [canes, glasses, hearing aids], no dentures or decayed fractured teeth, vermin infestation, medication deprivation or oversedation, deprivation of social contacts)


name: Determine whether the elder patient demonstrates signs of sexual abuse (e.g., presence of semen or dried blood, injury to external genitals, acquired sexually transmitted diseases, dramatic behavioral or health changes of undetermined etiology)


name: Determine whether the elder patient demonstrates signs of exploitation (e.g., inadequate provision for basic needs when adequate resources are available, deprivation of personal possessions, unexplained loss of Social Security or pension checks, lack of knowledge of personal finances or legal matters)


name: Determine whether acute symptoms in patient abate when they are separated from caretakers


name: Monitor for extreme compliance to caretakers' demands or passive submission to invasive procedures


name: Help patients and their families identify coping strategies for stressful situations, including the difficult decision to discontinue home care


name: Assist with restoration of full range of activities of daily living, as possible


name: Implement strategies to enhance critical thinking, decision-making, and remembering


name: Provide elder patients and their caretakers with community resource information (e.g., addresses and phone numbers of agencies that provide senior service assistance, home health care, residential care, respite care, emergency care, housing assistance, transportation, substance abuse treatment, sliding-fee counseling services, food pantries and Meals on Wheels, clothing distribution centers)


name: Identify individuals who are dependent on religious "leader" due to impaired or altered religious development, mental or emotional impairment, depression, substance abuse, lack of social resources, or financial issues


name: Monitor trends in arterial pH, PaCO2, and HCO3 to determine particular type of imbalance (e.g., respiratory or metabolic) and compensatory physiological mechanisms present (e.g., pulmonary or renal compensation, physiological buffers)


name: Maintain concurrent examination of arterial pH and plasma electrolytes for accurate treatment planning


name: Obtain ordered specimen for laboratory analysis of acid-base balance (e.g., ABGs, urine, and serum), as appropriate


name: Monitor for potential etiologies before attempting to treat acid-base imbalances as it is more effective to treat etiology than imbalance


name: Determine pathologies needing direct intervention versus those requiring supportive care


name: Monitor for complications of corrections of acid-base imbalances (e.g., rapid reduction in chronic respiratory alkalosis resulting in metabolic acidosis)


name: Monitor for mixed acid-base derangements (e.g., primary respiratory alkalosis and primary metabolic acidosis)


name: Provide for adequate hydration and restoration of normal fluid volumes, if necessary


name: Provide for restoration of normal electrolyte levels (e.g., potassium and chloride), if necessary


name: Administer prescribed medications as based on trends in arterial pH, PaCO2, HCO3, and serum electrolytes, as appropriate


name: Monitor for potential etiologies before attempting to treat acid-base imbalances (i.e., it is more effective to treat etiology than imbalance)


name: Monitor for causes of HCO3 deficit or hydrogen ion excess (e.g., methanol or ethanol ingestion, uremia, diabetic ketoacidosis, alcoholic ketoacidosis, lactic acidosis, sepsis, hypotension, hypoxia, ischemia, isoniazid or iron ingestion, salicylate toxicity, diarrhea, hyperalimentation, hyperparathyroidism)


name: Calculate anion gap to assist in determining causes of metabolic acidosis (e.g., nonanion gap indicates electrolyte influenced causes; anion gap indicates loss of bicarbonate causes)


name: Use mnemonics to assist in determining causes of metabolic acidosis (e.g., MUDPILES: Methanol ingestion, Uremia, Diabetic, alcoholic, or starvation ketoacidosis, Paraldehyde ingestion, Isoniazid or iron poisoning, Lactic acidosis, Ethylene glycol ingestion, Salicylate ingestion; HARDUP: Hyperalimentation, Acetazolamide, Renal tubular acidosis, renal insufficiency, Diarrhea and diuretics, Ureteroenterostomy, Pancreatic fistula)


name: Monitor for signs and symptoms of worsening HCO3 deficit or hydrogen ion excess (e.g., Kussmaul-Kien respirations, weakness, disorientation, headache, anorexia, coma, urinary pH level less than 6, plasma HCO3 level less than 22 mEq/L, plasma pH level less than 7.35, base excess less than -2 mEq/L, associated hyperkalemia, and possible CO2 deficit)


name: Administer fluids as indicated for excessive losses from underlying condition (e.g., diarrhea, diuretics, hyperalimentation)


name: Use parenteral HCO3 agents cautiously in premature infants, neonates, and small children


name: Prevent complications from excessive HCO3 administration (e.g., metabolic alkalosis, hypernatremia, volume overload, decreased oxygen delivery, decreased cardiac contractility, and enhanced lactic acid production)


name: Administer prescribed insulin, fluid hydration (isotonic and hypotonic) and potassium for treatment of diabetic ketoacidosis, as appropriate


name: Administer prescribed medications for treatment of inappropriate substance ingestion (e.g., alcohol, salicylate, ethylene glycol) or renal insufficiency


name: Monitor determinants of tissue oxygen delivery (e.g., PaO2, SaO2, hemoglobin levels, and cardiac output), as appropriate


name: Monitor for decreasing bicarbonate and acid buildup from excessive nonvolatile acids (e.g., renal failure, diabetic ketoacidosis, tissue hypoxia, and starvation), as appropriate


name: Prepare renal failure patient for dialysis (i.e., assist with catheter placement for dialysis), as appropriate


name: Monitor for CNS manifestations of worsening metabolic acidosis (e.g., headache, drowsiness, decreased mentation, seizures, and coma), as appropriate


name: Monitor for cardiopulmonary manifestations of worsening metabolic acidosis (e.g., hypotension, hypoxia, arrhythmias, and Kussmaul-Kien respiration), as appropriate


name: Monitor for GI manifestations of worsening metabolic acidosis (e.g., anorexia, nausea, and vomiting), as appropriate


name: Provide adequate nutrition for patients experiencing chronic metabolic acidosis


name: Monitor calcium and phosphate levels for patients experiencing chronic metabolic acidosis to prevent bone loss


name: Monitor for causes of HCO3 buildup or hydrogen ion loss (e.g., gastric fluid loss, vomiting, NG drainage, persistent diarrhea, loop or thiazide diuretics, cystic fibrosis, posthypercapnia syndrome in mechanically ventilated patients, primary aldosteronism, excessive ingestion of licorice)


name: Use mnemonics to assist in determining causes of metabolic alkalosis (e.g., DAMPEN: Diuretics, Adenoma secretor, Miscellaneous including Bartter's syndrome, penicillin, potassium deficiency, bulimia, Posthypercapnia, Emesis, Nasogastric tube; A BELCH: Alkali ingestion with decreased glomerular filtration rate, 11-B-hydroxylase deficiency, Exogenous steroids, Licorice ingestion, Cushing's syndrome and disease, Hyperaldosteronism)


name: Obtain ordered specimen for laboratory analysis of acid-base balance, as appropriate


name: Monitor arterial blood gases and serum and urine electrolyte levels, as appropriate


name: Administer dilute acid (e.g., isotonic hydrochloride, arginine monohydrochloride), as appropriate


name: Administer chloride to replace deficient anion (e.g., ammonium chloride, arginine hydrochloride, normal saline), as appropriate


name: Administer potassium-sparing diuretics (e.g., spironolactone and triamterene), as appropriate


name: Monitor for complications of corrections of acid-base imbalances (i.e., rapid reduction in metabolic alkalosis results in metabolic acidosis)


name: Monitor for mixed acid-base derangements (e.g., primary metabolic alkalosis and primary respiratory acidosis) presenting as inappropriate metabolic compensations shrouding a primary respiratory disorder


name: Calculate differences in observed HCO3 and expected change in HCO3 to determine presence of mixed acid-base derangement


name: Monitor for associated excesses of bicarbonate (e.g., hyperaldosteronism, glucocorticoid excess, licorice abuse), as appropriate


name: Monitor for neurological and/or neuromuscular manifestations of metabolic alkalosis (e.g., seizures, confusion, stupor, coma, tetany, hyperactive reflexes)


name: Monitor for pulmonary manifestations of metabolic alkalosis (e.g., bronchospasm, hypoventilation)


name: Monitor for cardiac manifestations of metabolic alkalosis (e.g., arrhythmias, reduced contractility, decreased cardiac output)


name: Monitor for GI manifestations of metabolic alkalosis (e.g., nausea, vomiting, diarrhea)


name: Monitor for possible causes of carbonic acid excess and respiratory acidosis (e.g., airway obstruction, depressed ventilation, CNS depression, neurological disease, chronic lung disease, musculoskeletal disease, chest trauma, pneumothorax, respiratory infection, ARDS, cardiac failure, acute opioid ingestion, use of respiratory depressant drugs, obesity hypoventilation syndrome)


name: Monitor for signs and symptoms of carbonic acid excess and respiratory acidosis (e.g., hand tremor with extensions of arms, confusion, drowsiness progressing to coma, headache, slowed verbal response, nausea, vomiting, tachycardia, warm sweaty extremities, pH level less than 7.35, PaCO2 level greater than 45 mm Hg, associated hypochloremia, and possible HCO3 excess)


name: Administer medication therapy aimed at reversing the effects of inappropriate sedative drugs (e.g., naloxone to reverse narcotics, flumazenil to reverse benzodiazepines), as appropriate


name: Maintain caution when reversing the effects of benzodiazepines to avoid seizures if reversal is accomplished too vigorously


name: Administer low flow oxygen and monitor for CO2 narcosis in cases of chronic hypercapnia (e.g., COPD)


name: Administer noninvasive, positive-pressure ventilation techniques (e.g., nasal continuous positive-pressure ventilation, nasal bilevel ventilation) for hypercapnia related to obesity hypoventilation syndrome or musculoskeletal disease


name: Monitor for hypoventilation and treat causes (e.g., inappropriate low-minute mechanical ventilation, chronic reduction in alveolar ventilation, COPD, acute opioid ingestion, obstructive or restrictive airway diseases)


name: Monitor determinants of tissue oxygen delivery (e.g., PaO2, SaO2, hemoglobin levels, cardiac output) to determine the adequacy of arterial oxygenation


name: Position patient for optimum ventilation-perfusion matching (e.g., good lung down, prone, semi-Fowler's), as appropriate


name: Monitor work of breathing (e.g., respiratory rate, heart rate, use of accessory muscles, diaphoresis)


name: Provide low-carbohydrate, high-fat diet to reduce CO2 production, if indicated


name: Promote adequate rest periods (e.g., 90 minutes of undisturbed sleep, organize nursing cares, limit visitors, coordinate consults), as appropriate


name: Monitor for hyperventilation and treat causes (e.g., inappropriate high-minute mechanical ventilation, anxiety, hypoxemia, lung lesions, severe anemia, salicylate toxicity, CNS injury, hypermetabolic states, GI distention, pain, high altitude, septicemia, stress)


name: Reduce oxygen consumption by promoting comfort, controlling fever, and reducing anxiety to minimize hyperventilation, as appropriate


name: Provide rebreather mask for hyperventilating patient, as appropriate


name: Reduce high-minute ventilation (e.g., rate, mode, tidal volume) in mechanically overventilated patients, as appropriate


name: Promote adequate rest periods of at least 90 minutes of undisturbed sleep (e.g., organized nursing cares, limited visitors, coordinated consults), as appropriate


name: Administer parenteral chloride solutions to reduce HCO3 when correcting the cause of respiratory alkalosis, as appropriate


name: Monitor trends in arterial pH, PaCO2, and HCO3 to determine effectiveness of interventions


name: Monitor for symptoms of worsening respiratory alkalosis (e.g., alternating periods of apnea and hyperventilation, increasing anxiety, increased heart rate without increased blood pressure, dyspnea, dizziness, tingling in extremities, hyperreflexia, frequent sighing and yawning, blurred vision, diaphoresis, dry mouth, pH level of greater than 7.45, PaCO2 less than 35 mm Hg, associated hyperchloremia, HCO3 deficit)


name: Monitor for hypophosphatemia and hypokalemia associated with respiratory alkalosis, as appropriate


name: Monitor for mixed acid-base derangements (e.g., primary respiratory alkalosis and primary metabolic acidosis) presenting as inappropriate respiratory compensations shrouding a primary metabolic disorder


name: Calculate differences in observed PaCO2 and expected change in PaCO2 to determine presence of mixed acid-base derangement


name: Monitor for neurological and/or neuromuscular manifestations of respiratory alkalosis (e.g., paresthesias, tetany, seizures), as appropriate


name: Monitor for cardiopulmonary manifestations of respiratory alkalosis (e.g., arrhythmias, decreased cardiac output, hyperventilation)


name: Administer sedatives, pain relief, and antipyretics, as appropriate


name: Administer neuromuscular-blocking agents only if patient is mechanically ventilated, if indicated


name: Obtain ordered specimen for laboratory analysis of acid-base balance (e.g., ABGs, urine, and serum) in at-risk populations, as appropriate


name: Obtain sequential specimens to determine trends


name: Analyze trends in serum pH in the patient experiencing conditions with escalating effects on pH levels (e.g., hyperventilating patients, diabetic or alcoholic ketoacidosis patients, septic patients)


name: Analyze trends in serum pH in at-risk populations (e.g., patients with compromised respiratory status, renal impairment, diabetes mellitus, prolonged diarrhea or vomiting, Cushing's syndrome)


name: Note if arterial pH level is on the alkaline or acidotic side of the mean (7.35-7.45)


name: Examine trends in serum pH in conjunction with PaCO2 and HCO3 trends to determine whether the acidosis or alkalosis is compensated or uncompensated


name: Note if the compensation is pulmonary, metabolic, or is physiologically buffered


name: Identify potential etiologies before attempting to treat acid-base imbalances as it is more effective to treat etiology than imbalance


name: Identify the presence or absence of an anion gap (greater than 14 mEq/L) signaling an increased production or decreased excretion of acid products


name: Monitor for signs and symptoms of HCO3 deficit and metabolic acidosis (e.g., Kussmaul-Kien respirations, weakness, disorientation, headache, anorexia, coma, urinary pH level less than 6, plasma HCO3 level less than 22 mEq/L, plasma pH level less than 7.35, base excess less than -2 mEq/L, associated hyperkalemia, and possible CO2 deficit)


name: Monitor for causes of metabolic acidosis (e.g., methanol or ethanol ingestion, uremia, diabetic ketoacidosis, alcoholic ketoacidosis, paraldehyde ingestion, lactic acidosis, sepsis, hypotension, hypoxia, ischemia, malnutrition, diarrhea, renal failure, hyperalimentation, hyperparathyroidism, salicylate toxicity, ethylene glycol ingestion)


name: Monitor for signs and symptoms of HCO3 excess and metabolic alkalosis (e.g., numbness and tingling of the extremities, muscular hypertonicity, shallow respirations with pause, bradycardia, tetany, urinary pH level greater than 7, plasma HCO3 level greater than 26 mEq/L, plasma pH level greater than 7.45, BE greater than 2 mEq/L, associated hypokalemia, and possible CO2 retention)


name: Monitor for causes of metabolic alkalosis (e.g., diuretics, emesis, nasogastric tube, posthypercapnia, potassium deficiency, alkali ingestion, Cushing's syndrome, hyperaldosteronism, hypochloremia, excessive ingestion of medications containing HCO3)


name: Monitor for signs and symptoms of PaCO2 level deficit and respiratory alkalosis (e.g., frequent sighing and yawning, tetany, paresthesia, muscular twitching, palpitations, tingling and numbness, dizziness, blurred vision, diaphoresis, dry mouth, convulsions, pH level greater than 7.45, PaCO2 less than 35 mm Hg, associated hyperchloremia, and possible HCO3 deficit)


name: Monitor for causes of respiratory alkalosis (e.g., hyperventilation, mechanical overventilation, hepatic disease, pregnancy, septicemia, pain, CNS lesions, and fever)


name: Monitor for signs and symptoms of PaCO2 level excess and respiratory acidosis (e.g., hand tremor with extensions of arms, confusion, drowsiness progressing to coma, headache, slowed verbal response, nausea, vomiting, tachycardia, warm sweaty extremities, pH level less than 7.35, PaCO2 level greater than 45 mm Hg, associated hypochloremia, and possible HCO3 excess)


name: Monitor for possible causes of respiratory acidosis (e.g., airway obstruction, depressed ventilation, CNS depression, neurological disease, chronic lung disease, musculoskeletal disease, chest trauma, infection, ARDS, cardiac failure, acute opioid ingestion, and use of respiratory depressant drugs)


name: Initiate and/or change medical treatment to maintain patient parameters within limits ordered by the physician, using established protocols


name: Determine patient ability to participate in specific activities


name: Collaborate with occupational, physical, or recreational therapists in planning and monitoring an activity program, as appropriate


name: Determine patient's commitment to increasing frequency and range of activity


name: Assist patient to choose activities and achievement goals for activities consistent with physical, psychological, and social capabilities


name: Encourage creative activities, as appropriate


name: Assist patient to schedule specific periods for activities into daily routine


name: Assist patient and family to identify deficits in activity level


name: Identify strategies to promote patient participation in desired activities


name: Coordinate patient selection of age-appropriate activities


name: Provide activities to increase attention span in consultation with occupational therapist


name: Facilitate activity substitution when patient has limitations in time, energy, or movement, in consultation with occupational, physical, or recreational therapists


name: Encourage involvement in group activities or therapies, as appropriate


name: Refer to community centers or activity programs, as appropriate


name: Promote a physically active lifestyle to avoid unneeded weight gain, as appropriate


name: Suggest methods of increasing daily physical activity, as appropriate


name: Provide activities with implicit and emotional memory components (e.g., specially selected religious activities) for dementia patients, as appropriate


name: Employ animal-assisted activity programs, as appropriate


name: Instruct family to provide positive reinforcement for participation in activities


name: Allow for family participation in activities, as appropriate


name: Assist patient to develop self-motivation and reinforcement


name: Monitor emotional, physical, social, and spiritual response to activity


name: Assist patient and family to monitor own progress toward goal achievement


name: Decide on purpose of acupressure for prevention or treatment of a particular individual (e.g., pain, headaches, nausea, asthma, colds and flu, arthritis, allergies, nervous tension, menstrual cramps, sinus problems, sprains, tennis elbow)


name: Describe the rationale, benefits, limits, and types of acupressure available (e.g., Shiatsu, Tui Na, Sujok, Jin Shin, Atmena)


name: Provide detailed description of chosen acupressure technique


name: Create a quiet, nondisrupting environment, when possible


name: Suggest that the individual assume a comfortable position with unrestricted clothing


name: Explain to individual that you will be searching for a tender area


name: Apply firm finger pressure in a slow, rhythmic manner to enable the layers of tissue to respond


name: Use thumbs, fingers, palms, the side of the hand, or knuckles to apply steady, stationary pressure at the pressure sensitive spot in the general location of the acupoint by using one's body weight to lean into the point to which pressure is applied


name: Apply pressure gradually and hold without any movement for several minutes at a time to relax an area or relieve pain


name: Observe verbal or postural cues (e.g., wincing, "ouch") to identify desired point or location


name: Instruct family/significant other(s) to provide acupressure treatments


name: Use personal protective equipment (PPE) (gloves, goggles, and mask), as appropriate


name: Position patient and head, as appropriate


name: Insert a laryngeal mask airway (LMA), as appropriate


name: Encourage physicians to place ETs via the oropharyngeal route, as appropriate


name: Hyperoxygenate with 100% oxygen for 3 to 5 minutes, as appropriate


name: Observe for systematic chest wall movement


name: Monitor oxygen saturation (SpO2) by noninvasive pulse oximetry and CO2 detection


name: Monitor respiratory status, as appropriate


name: Use personal protective equipment (e.g., gloves, goggles, and mask), as appropriate


name: Hyperoxygenate with 100% oxygen for at least 30 seconds, using the ventilator or manual resuscitation bag before and after each pass


name: Hyperinflate using tidal volumes that are indexed to the size of the patient, as appropriate


name: Use closed-system suctioning, as indicated


name: Use the lowest amount of wall suction necessary to remove secretions (e.g., 80-120 mm Hg for adults)


name: Monitor patient's oxygen status (SaO2 and SvO2 levels), neurological status (e.g., mental status, ICP, cerebral perfusion pressure [CPP]) and hemodynamic status (e.g., MAP level and cardiac rhythms) immediately before, during, and after suctioning


name: Vary suctioning techniques based on the clinical response of the patient


name: Monitor and note secretion color, amount, and consistency


name: Observe for signs of inadequate amniotic fluid volume (e.g., oligohydramnios, asymmetrical intrauterine growth retardation, postdatism, known fetal urinary tract abnormalities, prolonged rupture of membranes)


name: Recognize potential contraindications for amnioinfusion (e.g., amnionitis, polyhydramnios, multiple gestation, severe fetal distress, fetal scalp pH less than 7.20, known fetal anomaly, known uterine anomaly)


name: Observe for variable or prolonged fetal heart decelerations during intrapartal electronic monitoring


name: Obtain cord blood gas levels at time of delivery to evaluate effectiveness of intervention


name: Facilitate use of a pressure-relieving mattress


name: Monitor for phantom limb pain (i.e., check for burning, cramping, throbbing, crushing, or tingling pain where the limb was)


name: Administer pharmacological and nonpharmacological (e.g., TENS, phonophoresis, and massage) pain control, as needed


name: Monitor for psychological concerns (e.g., depression and anxiety) and adjustment related to change in body image


name: Place affected area in whirlpool bath, as appropriate


name: Monitor tissue for skin integrity (e.g., fungal infection, contact dermatitis, and scar management)


name: Instruct patient how to correctly perform postsurgical exercises (e.g., range of motion, endurance, and strengthening)


name: Encourage patient to perform range-of-motion, endurance, and strengthening exercises after surgery, providing assistance, when necessary


name: Instruct in transfer techniques and assistive devices (e.g., trapeze)


name: Facilitate the identification of needed modifications in lifestyle and assistive devices (e.g., home and car)


name: Instruct patient on signs and symptoms to be reported to health care provider (e.g., chronic pain, skin breakdown, tingling, absent peripheral pulse, cool skin temperature, and changes in functional needs or goals)


name: Discuss potential long-term goals for rehabilitation (e.g., walking without a support device)


name: Encourage and facilitate interaction with persons with similar amputations, as appropriate


name: Supervise initial use and care of the prosthesis


name: Instruct patient and family how to care for and apply the prosthesis


name: Assess prosthesis regularly for stability, ease of movement, energy efficiency, and gait appearance


name: Remove prosthesis before surgery, as appropriate


name: Refer to specialist for modification of prosthesis or treatment of complications related to its use


name: Establish effective communication patterns among patient, family, and caregivers to achieve adequate pain management


name: Ensure holistic approach to pain management (i.e., adequate consideration of physiological, social, spiritual, psychological, and cultural influences)


name: Adapt pain monitoring techniques to accommodate patients with communication impairments (e.g., pediatric, elderly, cognitively impaired, psychotic, critically ill, non-English speaking, dementia)


name: Determine pain onset, location, duration, characteristics, quality, intensity, pattern, relief measures, contributing symptoms, effects on patient, and severity before medicating patient


name: Determine patient's current level of comfort and desired level of comfort, using an appropriate pain rating scale


name: Determine patient's previous doses and routes of analgesic administration to avoid undertreatment or overtreatment


name: Involve patient in selection of analgesic, route, and dose, as appropriate


name: Assure that patient is not at risk for NSAID use (e.g., history of GI bleeding or renal insufficiency)


name: Assure that patient is not at risk for opioid use (e.g., history of obstructive or central sleep apnea)


name: Assure accurate 24-hour dosage is maintained (e.g., no more than 4000 mg acetaminophen and acetylsalicylic acid [ASA]; 3200 mg for ibuprofen)


name: Titrate opioid to desired effect or to uncontrollable side effects (e.g., comfort versus respiratory depression)


name: Adjust dosages for children and older adults, as appropriate


name: Account for narcotics and other restricted drugs, according to agency protocol


name: Record pain level using appropriate pain scale before and after administering analgesics


name: Attend to comfort needs and other activities that assist relaxation to facilitate response to analgesia


name: Assist patient in selecting nonpharmacological activities that have relieved pain in the past (e.g., distraction, music, simple relaxation therapy)


name: Give analgesics before pain-producing procedures or activities


name: Administer adjuvant analgesics and medications to potentiate analgesia, when needed


name: Instruct to request PRN pain medication before the pain is severe


name: Correct misconceptions and myths patient or family members may hold regarding analgesics, particularly opioids (e.g., addiction and risks of overdose)


name: Implement measures to reduce noxious stimuli in patient environment (i.e., keep patients clean, dry, correctly positioned, and turned regularly; prevent constipation and urinary retention; loosen constrictive bandages or clothing, as indicated; tighten and smooth wrinkled bed linens)


name: Evaluate the effectiveness of analgesic at regular, frequent intervals after each administration, but especially after the initial doses


name: Implement actions to decrease untoward effects of analgesics (e.g., respiratory depression, nausea and vomiting, dry mouth, constipation, gastric irritation)


name: Administer opioid reversal agents (e.g., naloxone) for respiratory depression or undesirable sedation, if indicated


name: Instruct patient and family about the use of analgesics, strategies to decrease side effects, and expectations for involvement in decisions about pain relief


name: Involve family/significant other(s) in pain control measures such as simple massage or heat/cold application techniques


name: Instruct patient and significant others about procedure


name: Check patency and function of intraspinal catheter, port, or pump


name: Label the intraspinal catheter and secure it appropriately


name: Ensure catheter site is visible and covered with a transparent dressing for monitoring purposes


name: Ensure that edges of site dressing are window-paned to prevent rolling of the dressing


name: Monitor catheter site and dressings to check for a loose catheter or wet dressing and notify appropriate personnel per agency protocol


name: Label tubing and site "Intraspinal Catheter-Do not Inject"


name: Avoid the use of alcohol on the catheter or connectors (i.e., alcohol is neurotoxic)


name: Start continuous infusion of analgesic agent after correct catheter placement has been verified and monitor rate to ensure delivery of prescribed dosage of medication


name: Monitor effectiveness of pain medication


name: Monitor respiratory status every hour for first 24 hours after catheter insertion, when patient is at highest risk for respiratory depression


name: Determine sensation every 2 hours using cold sensation with ice


name: Apply ice up from the toe and note where coldness is detected by the patient


name: Document numbness, tingling or normal sensation, and motor block using appropriate dermatomes


name: Determine the level of block to see if it is changing


name: Notify physician of sensation or motor block higher than the initial documented level


name: Identify weakness and sensation level for comparison (i.e., weakness should be correlated to the level of sensation)


name: Evaluate patient preoperatively in advance of the scheduled surgical procedure, preferably one or more days before procedure


name: Verify that the information provided by the patient is the same as the information in the identification device (e.g., wristbands, bed tag, fingerprint recognition software, palm vein scanner) and medical record


name: Examine patient and the patient's record to determine preexisting conditions, allergies, and contraindications for specific anesthetic agents or techniques


name: Document patient's readiness for anesthesia (e.g., preoperative fasting, medication regime, absence of upper respiratory tract infections, airway history)


name: Request appropriate consultations, including diagnostic and laboratory studies, based on the patient's health status and proposed surgery


name: Start appropriate intravenous and invasive monitoring lines and initiate noninvasive monitoring modalities, per the American Society of Anesthesiologists Standards for Basic Anesthetic Monitoring


name: Ensure positioning of patient to prevent peripheral nerve damage and pressure injuries


name: Deliver anesthetic consistent with each patient's physiological needs, patient's requests, clinical judgment, and the American Association of Nurse Anesthetists Scope and Standards for Nurse Anesthesia Practice


name: Monitor vital signs, respiratory and circulatory adequacy, response to anesthesia, and other physiological parameters


name: Measure and evaluate appropriate laboratory values


name: Manage emergence from anesthesia by administering indicated medications, fluids, and ventilatory support


name: Accompany patient to the postanesthesia or intensive care unit with appropriate monitoring and oxygen therapy


name: Encourage patient to seek assistance of nursing staff or responsible others during periods of increasing tension


name: Discourage intense activities (e.g., punching bag, pacing, excessive exercise)


name: Educate on methods to modulate experience of intense emotion (e.g., assertiveness training, relaxation techniques, writing in a journal, distraction)


name: Encourage use of collaboration to solve problems


name: Use external controls (e.g., physical or manual restraint, time outs, and seclusion) to calm patient who is expressing anger in a maladaptive manner, as needed (as last resort)


name: Assist the patient to identify possible upcoming, developmental, or situational crisis and the effects the crisis may have on personal and family life


name: Suggest printed literature and electronic sources for the patient to read, as appropriate


name: Schedule visits at strategic developmental or situational points


name: Include the family and significant others, when possible


name: Establish that the least restrictive measure is being initiated (if a lower level was used, establish that it was deemed ineffective before advancing to the next level of restriction)


name: Obtain a licensed independent practitioner (LIP) order as required by selection of measure based on institutional policy and state, federal, and regulatory agencies (e.g., Centers for Medicare & Medicaid Services, The Joint Commission)


name: Identify for the patient and significant others the appropriate behaviors necessary for termination of the intervention, repeat as needed


name: Restrict to designated area that is appropriate


name: Modulate human and environmental sensory stimuli (e.g., visiting sessions, sights, sounds, lighting, temperature, etc.) in the designated area, as needed


name: Use protective devices and measures (e.g., motion detectors, alarms, fences, gates, side rails, mitts, closed chairs, locked doors, restraints)


name: Administer PRN medications (e.g., anxiolytics, antipsychotics, sedatives), as appropriate


name: Provide for the patient's physical needs and safety (e.g., cardiovascular, respiratory, neurological, elimination, and nutrition, and skin integrity), as appropriate


name: Provide for the patient's psychological comfort and safety


name: Offer structured activities within the designated area, as appropriate


name: Provide positive reinforcement for appropriate behavior


name: Monitor the need for changes (e.g., lower/higher level measure, continue, or discontinue) to the restrictive measure at regular intervals


name: Involve patient in decision to change a restrictive measure (e.g., lower/higher level measure, continue, or discontinue), when appropriate


name: Hold a debriefing session (e.g., covering behaviors leading to the measures, and patient concerns about the intervention) with patient and staff after termination of the intervention


name: Document (e.g., rationale for the restrictive measure, patient's physical and psychological condition, nursing care provided, and the rationale for terminating the intervention) at appropriate points in care according to institutional policy, state, federal, and/or regulatory agency requirements


name: Identify form of art-based activity (e.g., preexisting, impromptu, directed, spontaneous)


name: Identify art medium to be used, such as drawings (e.g., self-portrait, human figure drawings, family kinetic drawings), photos and other media (e.g., photo journal, media journal), graphics (e.g., timeline, body maps), or artifacts (e.g., masks, sculpture)


name: Discuss with patient what to make, using direct or nondirect approach, as appropriate


name: Monitor patient's engagement during the art-making process, including verbal comments and behaviors


name: Record patient interpretation of drawings or artistic creation


name: Encourage patient to describe and talk about the art product and the art-making process


name: Incorporate patient's description and interpretation of the art activity into patient assessment data


name: Compare art product and art-making process to patient's developmental level and prior art making activities


name: Provide referral (e.g., social work, art therapy), as indicated


name: Provide 100% humidification of inspired air, oxygen, or gas


name: Inflate endotracheal/tracheostomy cuff using minimal occlusive volume (MOV) technique or minimal leak technique (MLT)


name: Maintain inflation of the endotracheal/tracheostomy cuff at 15 to 25 mm Hg during mechanical ventilation and during and after feeding


name: Monitor cuff pressures every 4 to 8 hours during expiration using a three-way stopcock, calibrated syringe, and manometer


name: Check cuff pressure immediately after delivery of any general anesthesia or manipulation of endotracheal tube


name: Suction the oropharynx and secretions from the top of the tube cuff before deflating the cuff


name: Change endotracheal tapes/ties every 24 hours, inspect the skin and oral mucosa, and reposition ET to the other side of the mouth


name: Loosen commercial endotracheal tube holders at least once a day and provide skin care


name: Assist with chest x-ray examination to monitor position of tube, as needed


name: Monitor secretions color, amount, and consistency


name: Perform oral care (e.g., use toothbrush, swabs, mouth and lip moisturizer), as needed


name: Monitor for decrease in exhale volume and increase in inspiratory pressure in patients receiving mechanical ventilation


name: Provide trachea care every 4 to 8 hours, as appropriate: clean the inner cannula, clean and dry the area around the stoma, and change tracheostomy ties


name: Inspect and palpate for air under skin every 8 hours


name: Tape the tracheostomy obturator to head of bed


name: Tape a second tracheostomy (same type and size) and forceps to head of bed


name: Elevate head of the bed equal to or greater than 30 degrees or assist patient to a sitting position in a chair during feedings, as appropriate


name: Minimize use of medications known to delay gastric emptying, as appropriate


name: Position upright equal to or greater than 30 (NG feedings) to 90 degrees or as far as possible


name: Keep tracheal cuff inflated, as appropriate


name: Supervise eating or assist, as necessary


name: Check NG or gastrostomy residual before feeding


name: Avoid feeding, if residuals are high (e.g., greater than 250 cc for feeding tubes or greater than 100 cc PEG tubes)


name: Use continuous NG pump feedings in place of gravity or bolus, if appropriate


name: Inspect oral cavity for retained food or medications


name: Determine barriers to assertiveness (e.g., developmental stage, chronic medical or psychiatric condition, lack of knowledge, and female socialization)


name: Differentiate between assertive, aggressive, passive, and passive-aggressive behaviors


name: Help to identify nonverbal communication (e.g., smiling, eye contact, tone and volume of voice) that will assist or hinder assertiveness


name: Help to build communication skills that will enable the patient to accurately articulate information


name: Encourage verbalization of feelings about diagnosis, treatment, and effect on lifestyle


name: Discuss with patient culture-based expressions of attachment before and after birth


name: Determine patient's image of unborn child


name: Discuss patient's experience of hearing fetal heart tones


name: Discuss patient's experience of viewing fetal ultrasound image


name: Discuss patient's experience of fetal movements


name: Encourage patient to attend prenatal classes


name: Instruct patient's partner on ways to participate during labor and delivery


name: Place newborn skin-to-skin with parent immediately after birth


name: Provide opportunity for parent to see, hold, and examine newborn immediately after birth (i.e., delay unnecessary procedures and provide privacy)


name: Facilitate eye contact between parent and newborn immediately after birth (i.e., demonstrate en face positioning; dim room lights; and provide a quiet, private environment)


name: Complete maternal and newborn assessments while allowing parent to hold newborn


name: Share information gained from physical assessments of infant with parent


name: Inform parent of care being given to infant


name: Encourage mother to breastfeed, if appropriate


name: Provide adequate breastfeeding education and support, if appropriate


name: Instruct parent on infant cues for feeding (e.g., rooting, sucking on fingers, crying)


name: Instruct parent on importance of feeding as nurturing activity, as it provides opportunity for extended eye contact and physical closeness


name: Assist parent in identifying infant's need when crying (e.g., hunger, pain, fatigue, fussiness)


name: Encourage consistent, prompt response to infant crying


name: Demonstrate infant soothing techniques to parent


name: Point out infant cues that show responsiveness to parent


name: Encourage frequent, sustained physical closeness between infant and parent (e.g., skin-to-skin contact, breastfeeding, child carrying, and sleeping in close proximity to infant)